Basic information
- CAS
672-87-7- Standard SMILES
C[C@](N)(Cc1ccc(O)cc1)C(=O)O- InChIKey
NHTGHBARYWONDQ-JTQLQIEISA-N- Molecular formula
- C10H13NO3
- Average molar mass
- 195.21 g/mol
- Monoisotopic mass
- 195.08954328
Overview
Alpha-methyl-L-tyrosine is an L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. It has a role as an antihypertensive agent and an EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor. It is a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid.
Names & identifiers
- Preferred name
- Metyrosine
- IUPAC
- (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
- English name
- alpha-Methyl-L-p-tyrosine
- Molecular formula
- C10H13NO3
- Molecular weight
- 195.22
Names & synonyms
Show more names
Database identifiers
- CAS
672-87-7- PubChem CID
- 441350
- DTXSID
DTXSID6023315- ChEMBL
CHEMBL1200862- ChEBI
CHEBI:6912- UNII
- DOQ0J0TPF7
- EC Number
- 211-599-5
- Nikkaji
- J9.465J
Properties
Computed structural properties
- XLogP
- -1.6
- Topological polar surface area
- 83.6 Ų
- Hydrogen bond donors
- 3
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 3
- Heavy atoms
- 14
- Formal charge
- 0
- Complexity
- 211
Experimental & physicochemical properties
Solubility
Very slightly soluble
2.48e+00 g/L
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physicochemical properties
- Melting point
- 320 · 320-340°C dec.
- Boiling point
- 383.7 · 383.7±32.0 °C(Predicted)
- Density
- 1.283 · 1.283±0.06 g/cm3(Predicted)
- storage temp.
- -20 °C · -20°C
- solubility
- Aqueous Acid (Slightly)
- form
- Powder
- pka
- 2.7 · pKa 2.7 (Uncertain);10.1 (Uncertain)
- color
- White to pale yellow
- optical activity
- -3.6 ° · -3.60°(C=0.01g/ml 1N HCL)
- Merck
- 13 · 13,6183
- BRN
- 2368400 · 2368400
- InChI
- InChI=1/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/s3
- InChIKey
- NHTGHBARYWONDQ-JTQLQIEISA-N
- SMILES
- C(C1C=CC(O)=CC=1)[C@@](N)(C)C(=O)O |&1:8,r|
- CAS DataBase Reference
- 672 · 672-87-7(CAS DataBase Reference)
- FDA UNII
- 0 J0TPF7 · DOQ0J0TPF7
- NCI Drug Dictionary
- DEMSER
- ATC code
- 2 KB01 · C02KB01
- UNSPSC Code
- 41116107 · 41116107
- NACRES
- 32 · NA.32
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 315 · H315-H319
- Precautionary statements
- 261 · P261-P281-P305+P351+P338
- PPE
- 95 · Eyeshields, Gloves, type N95 (US)
- Risk Statements
- 22 · 22-38-40-48/20/22
- Safety Statements
- 22 · 22-24/25
- WGK Germany
- 3 · 3
- TSCA
- No
- HS Code
- 2922504500 · 2922504500
- Storage Class
- 11 · 11 - Combustible Solids
Safety & regulation
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P270, P271, P301+P317, P304+P340, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard information
Toxicology
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Metyrosine
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
Safety data
- PPE
- Eyeshields, Gloves, type N95 (US)
- wgk
- 3
- tsca
- No
- hs_code
- 2922504500
- risk_code
- 22-38-40-48/20/22
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- safety_code
- 22-24/25
- Storage Class
- 11 - Combustible Solids
- Hazard statements
- H315-H319
- Precautionary statements
- P261-P281-P305+P351+P338
Chemistry & industry
Pharmacology
ATC Code
C - Cardiovascular system
QC - Cardiovascular system
Pharmacodynamics
In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after metyrosine is discontinued. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.
Mechanism of Action
Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure.
FDA Pharmacological Classification
DOQ0J0TPF7
METYROSINE
Established Pharmacologic Class [EPC] - Catecholamine Synthesis Inhibitor
Mechanisms of Action [MoA] - Catecholamine Synthesis Inhibitors
Metyrosine is a Catecholamine Synthesis Inhibitor. The mechanism of action of metyrosine is as a Catecholamine Synthesis Inhibitor.
METYROSINE
Absorption, Distribution and Excretion
Well absorbed from the gastrointestinal tract.
Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.
Applications
Usesα-Methyl-L-tyrosine is used to determine whether Fe2/ methamphetamine (METH) -induced cell death is dependent on cytosolic dopamine and iron mediated oxidative stress.
UsesMetyrosine is the α-methyl derivative of tyrosine. It competitively inhibits tyrosine hydroxylase action, thus reducing the formation of epinephrine and norepinephrine. It is used for treating patients with pheochromocytoma, in cases where a rise in the level of catecholamines is observed.
UsesA tyrosine hydroxylase inhibitor. An antihypertensive in pheochromocytoma
General DescriptionMetyrosine (α-Methyl-L-tyrosine, Demser). Althoughinhibition of any of the three enzymes involved in CA biosynthesisshould decrease CAs, inhibitors of the first andthe rate-limiting enzyme TH would be the most effective.As such, metyrosine is a much more effective competitiveinhibitor of E and NE production than agents that inhibitany of the other enzymes involved in CA biosynthesis. Itis often possible to “fool” the enzymes into accepting astructurally similar and unnatural substrate such as metyrosine.Metyrosine differs structurally from tyrosine onlyin the presence of an α-methyl group . It is oneexample of a CA-biosynthesis inhibitor in clinical use.Although metyrosine is used as a racemic mixture, it is the (-)isomer that possesses the inhibitory activity.Metyrosine, which is given orally in dosages ranging from 1 to 4 g/day, is used principally for the preoperative managementof pheochromocytoma, chromaffin cell tumorsthat produce large amounts of NE and E. Although theseadrenal medullary tumors are often benign, patients frequentlysuffer hypertensive episodes. Metyrosine reducesthe frequency and severity of these episodes by significantlylowering CA production (35%–80%). The drug ispolar (log P=0.73) and excreted mainly unchanged in theurine. Because of its limited solubility in water caused byintramolecular bonding of the zwitterions, crystalluria is apotential serious side effect. It can be minimized by maintaininga daily urine volume of more than 2 L. Inhibitors ofCA synthesis have limited clinical utility because suchagents nonspecifically inhibit the formation of all CAs andresult in many side effects. Sedation is the most commonside effect of this drug.A similar example is the use of α-methyl-m-tyrosine inthe treatment of shock. It differs structurally from metyrosineonly in the presence of m-OH instead of p-OH inmetyrosine. This unnatural amino acid is accepted by the enzymesof the biosynthetic pathway and converted tometaraminol (an α-agonist).
Suppliers100 total
Additional notes
DefinitionChEBI: An L-tyrosine derivative that consists of L-tyrosine bering an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is us d to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.
Related reactions
Compound notes
Loading…